Our in vitro and in vivo modeling studies prompted us to assess whether DUSP1 can be considered as a potential therapeutic target for disorders featuring hallmarks of glucocorticoid resistance, one of which is hypercortisolemia. The gene discussed is DUSP1; the disease is adrenal gland hyperfunction.